Personalis (NASDAQ:PSNL) Now Covered by Analysts at Craig Hallum

Analysts at Craig Hallum began coverage on shares of Personalis (NASDAQ:PSNL) in a research report issued to clients and investors on Monday,Briefing.com Automated Import reports. The firm set a “buy” rating and a $8.00 price target on the stock. Craig Hallum’s price target would indicate a potential upside of 120.39% from the company’s previous close.

PSNL has been the subject of a number of other reports. Lake Street Capital boosted their price objective on shares of Personalis from $7.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of Personalis in a research note on Friday, February 28th. Finally, Needham & Company LLC dropped their price target on shares of Personalis from $7.25 to $7.00 and set a “buy” rating on the stock in a research note on Friday, February 28th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $7.80.

Personalis Stock Performance

Shares of NASDAQ:PSNL opened at $3.63 on Monday. The stock has a 50 day moving average price of $4.97 and a 200-day moving average price of $4.91. The firm has a market capitalization of $320.39 million, a P/E ratio of -2.16 and a beta of 1.73. Personalis has a 52-week low of $1.13 and a 52-week high of $7.20.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.09. The business had revenue of $16.80 million for the quarter, compared to analysts’ expectations of $15.48 million. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. On average, equities analysts forecast that Personalis will post -1.4 EPS for the current fiscal year.

Hedge Funds Weigh In On Personalis

Hedge funds have recently modified their holdings of the stock. Point72 Asia Singapore Pte. Ltd. bought a new stake in Personalis in the fourth quarter worth $28,000. Stifel Financial Corp boosted its stake in shares of Personalis by 25.0% during the 4th quarter. Stifel Financial Corp now owns 25,000 shares of the company’s stock worth $144,000 after purchasing an additional 5,000 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Personalis by 2,827.0% during the fourth quarter. JPMorgan Chase & Co. now owns 5,854 shares of the company’s stock valued at $34,000 after buying an additional 5,654 shares during the last quarter. Two Sigma Advisers LP increased its stake in Personalis by 25.6% in the fourth quarter. Two Sigma Advisers LP now owns 34,300 shares of the company’s stock worth $198,000 after purchasing an additional 7,000 shares during the period. Finally, Ameriprise Financial Inc. increased its stake in Personalis by 38.3% in the 4th quarter. Ameriprise Financial Inc. now owns 34,407 shares of the company’s stock worth $199,000 after buying an additional 9,535 shares during the period. Hedge funds and other institutional investors own 61.91% of the company’s stock.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.